Exogenous insulin-like growth factor 1 (IGF-l ) given centrally 2 h after severe hypoxic-ischemic injury to rats reduces loss of neurons (Gluckman et aI., 1992) . Insulin given immediately post ischemia also shows a similar protective response that is in dependent of its hypoglycemic effect (Voll and Auer, 1991) . However, given the high doses of in sulin used, these effects may be mediated through the type 1 IGF receptor on which insulin can act in high doses. The mode of this neuronal protective action of exogenous IGF-I and insulin after injury is unclear.
IGF-l is thought to play a paracrine role in the developing and mature brain (Werther et aI., 1990) . In vitro studies indicate that IGF-l is a potent non selective neurotrophic agent (Knusel et aI., 1990; Svrzic and Schubert, 1990) . Type 1 IGF receptors gions (p < 0.05), and 50 flog reduced the infarction rate from 87 to 26% (p < 0.01). Pretreatment did not alter outcome. IGF-l improved outcome compared with equi molar doses of insulin (p < 0.05) and did not affect sys temic glucose concentrations or cortical temperature. The results indicate that the neuronal protective effects of IGF-l are specific and are not mediated via insulin recep tors, hypothermia, or hypoglycemic mechanisms. Cen trally administered IGF-l appears to provide worthwhile trophic support to cells within most cerebral structures after transient hypoxic-ischemic injury. Key Words: Brain-Infarction-Insulin-like growth factor I-Isch emia.
are widespread in the eNS (Bohannon et aI., 1988; Bondy et ai., 1992) . These receptors mediate the anabolic and somatogenic effects of IGF-l and have a higher affinity for IGF -I compared to insulin (Hill et ai., 1986; Lesniak et ai., 1988) . From 3 days after injury, greatly increased levels of IGF-l are pro duced, particularly in the developing brain (Ya maguchi et ai., 1991; Gluckman et ai., 1992) . The effect of IGF-I as a central neuroprotectant when administered after an insult suggests a mode of ac tion involving interference with the activated pro cesses leading to cell death. Endogenous and exog enous IGF-I stimulate peripheral nerve regenera tion (Kanje et ai., 1989) . Presumably, IGF-I has a similar trophic role in the brain after injury.
Because of the potential clinical application to humans, the present study was undertaken to clar ify the mode of action and effects of central IGF-l and insulin treatment after hypoxic-ischemic injury. The aims of this study were first, to determine the dose-response characteristics of IGF-l treatment; second, to determine whether the neuroprotective effects were mediated via the insulin or type 1 IGF receptor; and third, to explore the relationship be tween IGF-l administration and the time of insult.
The effects of IGF-l treatment on blood glucose and brain temperature were also evaluated.
MATERIALS AND METHODS
These studies were approved by the Animal Ethical Committee of the University of Auckland. Briefly, a hyp oxic-ischemic injury of lO-min duration was induced in the right hemisphere of adult rats under thermo neutral conditions by a modification of the method of Levine (1960) . Four independent studies were performed (see Experimental Groups). Generally, vehicle alone or IGF-l was infused into the right lateral cerebral ventricle before or 2 h after hypoxia-ischemia, and histological outcome was analyzed 5 days later.
Hypoxic-ischemic injury model
Adult male Wistar rats (52-66 days old) weighing 260--320 g were prepared under 3% halothane/02 anesthesia. The right common carotid artery was exposed, separated, and ligated twice with 0/3 silk sutures. A guide cannula (21G x 6 mm) was fixed on the dura with dental cement and stainless-steel skull screws at 8.02 mm anterior from the stereotaxic zero reference point (Paxinos and Wat son, 1982 ) and 1.4 mm from midline on the right side. In selected rats, a temperature transmitter (Mini-Mitter XM FH-BP brain probe) was fixed at 4.5 mm anterior from stereotaxic zero and 3 mm from midline on the dura of the ligated side. Arterial blood samples were obtained during the surgery via left ventricular heart puncture, and the plasma was analyzed for glucose and lactate (230 YSI; Yellow Springs Instrument Co., Yellow Springs, OH, U.S.A.). For the preinsult treatment study, glucose and lactate measurements were determined from whole blood instead of plasma.
Rats recovered from anesthesia for 1 h at room tem perature and were then placed in an incubator at 30.5-3ISC and relative humidity 85-95% for another hour. They were exposed to 5.8-6.2% O2 hypoxia for 10 min. The rats were kept in the incubator for an additional 2 h at 31°C after the hypoxia-ischemia. Temperature was continuously measured via Mini-Mitter telemetric probes; averages were calculated and stored on disk at I-min intervals (Dale et aI., 1989) .
Injections into the right lateral cerebral ventricle were performed under light (1.5-2%) halothane/02 anesthesia at 1 ILl/min via a 12-mm 27G infusion cannula inserted in the guide cannula. Rats in each treatment group were exposed to hypoxia and infused simultaneously. The rats had free access to food and water throughout the exper iment and were killed at 120 h after hypoxia-ischemia with an overdose of sodium pentobarbital.
Quantification of brain damage
The brain was prepared for histological analysis as pre viously described (Klempt et aI., 1992) . Briefly, the brain was perfused in situ with 0.9% saline followed by FAM (formaldehyde, acetic acid, methanol 1: 1 :8). The brains were removed 1 h after perfusion and stored in F AM for at least 24 h before embedding in ParaPlast. The sections were stained with thionine/acid fuchsin (Auer et aI., 1985) .
The extent of neuronal loss was determined as de scribed elsewhere (Klempt et aI., 1992) . Briefly, this was done via light microscopy by two assessors, one of whom J Cereb Blood Flow Metab, Vol. 13, No.4, 1993 was blinded to the experimental groupings. Neurons showing ischemic-hypoxic cell change with acidophilic (red) cytoplasm (Auer et aI., 1985) and contracted nuclei (Brown and Brierley, 1972) were considered dead. The percentages of dead neurons in the frontoparietal cortex, striatum, hippocampal CAI-CA4 regions, and dentate gy rus (DG) were estimated from three sections (4.7, 3.5, 2.3 mm anterior from stereotaxic zero reference). The cortex was divided into six regions for assessment ( Fig. 1 ). Cor tical regions 2-5 were defined as the frontoparietal cortex (Fig. l) . The hippocampus was similarly divided into four regions, corresponding to CAl and CA2, CA3, CA4, and DG (Fig. 1) . The striatum was scored only on the section 4.7 mm anterior from stereotaxic zero.
The percentage of dead neurons was scored as follows: 0, no dead neurons; 1, <10%; 2, 10--50%; 3, 50--90%; 4, >90%; 5, no surviving neurons. To convert these scores to a ratio scale, the nominal damage score was taken as the midpoint of each of these ranges: 0, 5, 30, 70, 95,100, respectively. These scores were averaged to give a single damage score within each of the regions described above. All brains were also scored for the presence or absence and percentage of cortical infarction, defined as a region of parenchymal pan-necrosis due to death of glia as well as neurons. Rats that died between the infusion and the end of the experiment were excluded from histological analysis.
Experimental groups
Dose response. To clarify the dose-response effects of IGF-l treatment, 16 groups of four rats were treated with either 50, 5, 0.5, or 0 ILg (vehicle) recombinant human IGF-l (Dr. K. Nikolics, Genentech, South San Francis co, CA, U.S.A.). The IGF-l was given as a 20-ILI infusion over 20 min starting at 2 h after hypoxia-ischemia. The vehicle consisted of 0.1 M citrate buffer (in which the IGF-l was stored) diluted immediately before infusion with 0.15 M phosphate-buffered saline (PBS) and 0.1% bovine serum albumin (BSA), giving a final pH of 7.2-7.25.
To determine the effects of IGF-l treatment on the met abolic status of the rats, arterial plasma glucose and lac- tate concentrations were measured immediately preinfu sion and 1 h postinfusion for the vehicle-and 50 ILg IGF I-treated group.
In one additional rat cortical temperature was mea sured during the insult.
Specificity of action. To compare the effect of insulin treatment with IGF-1, 18 groups of three rats were treated with either 20 ILg IGF-1, 20 ILg insulin (Eli Lily, Indianap olis, IN, U.S.A.), or vehicle alone. These were given as a 1O-1L1 infusion over 10 min starting 2 h after the hypoxia ischemia. The vehicle was 0.1 N acetic acid (in which the growth factors were stored) diluted nine times immedi ately before infusion with 0.1 % BSA dissolved in 0.15 M PBS, giving a final pH of 7.2-7.25.
Effect of IGF-I on brain temperature. The temperature of the ipsilateral cortex was recorded during and for 18 h after hypoxia-ischemia in a separate group of nine 20 ILg IGF-l-treated and nine vehicle-treated rats. IGF-1 or ve hicle alone was given at 2 h after the hypoxia-ischemia, as described in the dose-response study. Recordings from three rats were rejected due to technical problems.
Time of administration. To evaluate the effect of pre insult administration of IGF-l, 11 pairs of rats were treated with either 20 ILg recombinant human IGF-l or vehicle alone. These were administered as a to-ILl infu sion given over to min at 1 h pre insult. The vehicle was 0.1 N acetic acid diluted 19 times immediately before in fusion with 0.1 % BSA dissolved in 0.15 M PBS, giving a final pH of 7.2-7.25.
Statistics
Two-way analysis of variance (ANOV A) followed by application of the protected least-significant-difference procedure for post hoc comparisons was used to compare rank-transformed (Conover and Iman, 1976) neuronal loss scores (with region as a repeated measure) between treatment groups. Infarction rate was compared using Fisher's exact test with the Bonferroni correction for multiple comparisons. ANOV A was used to compare physiologic variables between treatment groups, with time as a repeated measure for the temperature record ings. Where appropriate, results are presented as mean ± SD.
RESULTS

Systemic parameters
There were no significant differences between groups within each study in preinsult body weight and arterial glucose and lactate concentrations (Ta ble 1).
Experimental groups
Dose-response study. Five days after hypoxic ischemic injury, the vehicle-treated rats showed the most severe damage, in terms of either the inci dence of infarction (Fig. 2) or neuronal loss (Fig. 3) . Typically, neuronal loss was widespread through out the middle cerebral artery territory of the li gated hemisphere of vehicle-treated controls, in cluding the frontoparietal cortex, striatum, hippo campus, and DG (Fig. 3) . Cortical infarction was present in 13 of 15 vehicle-treated rats (Fig. 2) . Typ ically, this was apparent as full-thickness (gray mat ter) infarction that sometimes extended into the pir iform cortex, hippocampus, and dorsolateral thala mus and striatum (Fig. 4A ).
Five to 50 j.Lg IGF-I reduced (p < 0.05) the inci dence of cortical infarction in a dose-dependent manner (Fig. 2) . Similarly, there was an overall im provement in neuronal loss score after treatment with 5 and 50 j.Lg (Fig. 3) (p < 0.05). Dose depen dency was observed in all regions, with an improve ment in the neuronal loss score in the frontoparietal cortex, striatum, hippocampus, and DG following treatment with 50 j.Lg IGF-l (p < 0.05) (Fig. 3) . The mean cortical temperature during the hypoxia ischemia was 37.1 ± 1°C. Seven animals died during the experiment (Table 1) .
Treatment with 50 j.Lg IGF-l 2 h postinsult did not affect serum glucose concentrations (8.8 ± 0.5 mM; n = 6) compared with vehicle-treated controls (8.7 ± 0.5 mM; n = 6) measured I h after IGF-I infu sions.
Specificity of action. Treatment with 20 j.Lg of in sulin 2 h after hypoxia-ischemia did not significantly reduce the incidence of infarction in the cortex or neuronal loss compared with vehicle-treated rats (Figs. 5 and 6), whereas 20 j.Lg of IGF-I given 2 h after hypoxia-ischemia reduced overall neuronal loss compared with vehicle-and insulin-treated an- Vehicle temperature 300 ± 14 1.6 ± 0.5 6.4 ± 0.9 17 20 fJ,g IGF-l temperature 304 ± 10 1.5 ± 0.5 6.3 ± 0.7 19 Timing
Pre vehicle 298 ± 13 1.5 ± 0.6 5.9 ± 0.9 11 Pre 20 fJ,g IGF-l 300 ± 6 1.7 ± 0.6 6.4 ± 0.6 10 IGF-l, insulin-like growth factor I. imals (p < 0.05) (Fig. 5 ). Neuronal loss was signif icantly reduced in the IGF-l-treated animals in the frontoparietal cortex and hippocampus compared with those that had vehicle treatment (p < 0.05) (Fig. 5) . Similarly, the IGF-l loss scores were sig nificantly lower in the striatum and hippocampus compared with the insulin-treated animals (p < 0.05) (Fig. 5 ). IGF-l reduced the cortical infarction rate compared with vehicle-treated animals (p < 0.05) (Fig. 6) . One vehicle-treated rat died.
Effect of IGF-I on brain temperature. Treatment with 20 jJ.g IGF-l (n = 7) 2 h after hypoxia-ischemia did not significantly alter cortical temperature com pared with vehicle-treated controls (n = 8) over 18 h after the hypoxia-ischemia (Fig. 7) .
Time of administration. Histological outcome was not significantly different between vehicle in fusions and 20 jJ.g IGF-1 groups treated 1 h before hypoxia-ischemia (Fig. 8) . In a previous study, we have shown that 20 jJ.g IGF-l given 2 h after hyp oxia-ischemia improves histological outcome (Gluckman et aI., 1992) . The mean cortical temper ature during the hypoxia-ischemia was 38.0 ± 0.6°C. One IGF-l -treated rat died during the exper iment.
DISCUSSION
Type 1 IGF receptors occur throughout the CNS on both neurons and glia, with the highest density in the striatum and cortex (Hill et aI., 1986; Lesniak et aI., 1988) . IGF-l treatment reduced neuronal loss in the cortex, striatum, and dentate. This treatment J Cereb Blood Flow Metab, Vol. /3, No.4, 1993 also lowered the incidence of infarction, indicating that loss of glial cells was reduced. These results agree with in vitro studies indicating that IGF-l has potent nonselective trophic actions on neurons un der normal conditions and during hypoglycemic in sults (Knusel et aI., 1990; Cheng and Mattson, 1992) . Insulin has a much lower affinity for type 1 IGF receptors, competing with IGF-l only at 100fold higher concentrations (Gilmour et aI., 1988) . fL9 insulin-like growth factor 1 (IGF-1). The cross-hatched bars display the mean score. Overall neuronal loss was re duced following lateral ventricular infusions with 5 and 50 fLg IGF-1 2 h after hypoxia-ischemia (p < 0.05). Neuronal loss was reduced in the frontoparietal cortex, striatum, hippo campus, and dentate gyrus after treatment with 50 fLg IGF-1 (p < 0.05). FP Ctx, frontoparietal cortex; CA1-4, hippocam pal CA1-4 regions. *p < 0.05, **p < 0.01.
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FIG. 4. Representative Nissel-stained sections from vehicle (A) and 50 j.Lg insulin-like growth factor 1 (IGF-1)-(8) treated rats. Transient hypoxia-ischemia caused widespread neuro nal loss throughout the middle cerebral artery territory of the ligated hemisphere, including the frontoparietal cortex, hip pocampus, and striatum (A). Typically, there was infarction of the cortex, extending from the border of the sagittal cortex to, and occasionally into, the piriform cortex. Infarction also occurred in the hippocampus, striatum, and thalamus of a few animals. Treatment with 50 j.Lg IGF-1 2 h after hypoxia ischemia reduced the severity of neuronal loss, particularly in the cortex, striatum, hippocampal CA1-4 regions, and den tate (8).
Thus, our results indicate that the neuroprotective effects occur via IGF receptors (Fig. 5) .
Many previously described neuronal protective strategies have been found to be effective by induc ing hypothermia. A lowering of cortical tempera ture by as little as 1° C can improve outcome. IGF-I treatment did not alter cortical temperature, exclud ing the possibility of a hypothermia mechanism (Fig. 5) . Some studies suggest that hyperglycemia can worsen outcome by increasing lactate accumu lation, and it is possible that a hypoglycemic effect may be protective. IGF-l treatment did not signifi cantly affect systemic glucose concentrations at the doses used. Thus, a hypoglycemic mechanism is unlikely.
IGF-l given 1 h before hypoxia-ischemia did not alter outcome (Fig. 7) . The reason for the lack of effect is not obvious. Rat CSF is turned over about every 50 min, and the half-life of IGF-I is likely to be short due to tissue uptake. It is possible that it can act only at high concentrations to inhibit mech anisms once initiated. Thus, the lack of effect may be due to rapid turnover oflGF-I, leaving little ac tivity following injury.
Movement of peptide from the CSF into the brain parenchyma is thought to occur by simple diffusion. Movement by this process is thought to lead to very steep (l ,OOO-fold) concentration gradients over rel atively short distances of 1 mm into the parenchyma (Pardridge, 1991) . Given the greatly differing depths of the structures affected by treatment, it is unlikely that IGF-1 is moving to the site of action by simple diffusion alone ( Figs. 3 and 5 ). It is possible that the IGF-1 is reaching the sites of action via the periph- eral circulation and crossing the blood-brain barrier (Pardridge, 1991) . The IGF binding proteins may alter the kinetics of distribution. Hypoxic-ischemic injury changes the pattern of expression of IGF binding proteins with increased expression of bind ing proteins 2, 3, and 5 and inhibition of 4 (Beilharz et aI. , 1992; Gluckman et aI., 1992; Klempt et aI. , 1992) . Brief hypoxic-ischemic injuries trigger a cascade of processes that can lead to death of neurons and development of infarction over several days, whereas prolonged insults can cause immediate loss of neurons. During and immediately after the insult, several processes such as glutamate toxicity, cal cium accumulation, and free radical activity have been suggested to contribute to the injury. How ever, these mechanisms cannot clearly explain why neuronal death and development of infarcts are of ten delayed for many hours after the primary injury. An alternative hypothesis is that death of cells is triggered by loss of survival signals such as trophic factors after injury.
Electrical activity and trophic factors such as nerve growth factor and interleukin-1 interact to regulate neuronal survival in vitro (Koike et aI. , 1989; Brenneman et ai., 1992) . These factors are thought to suppress endogenous active death pro grams by maintaining intracellular Ca 2 + concentra tions (Koike et ai., 1989) . Some studies suggest that delayed neuronal death occurs via mechanisms sim ilar to programmed cell death following growth fac tor deprivation (Martin et ai., 1988; Shigeno et ai., 1990) . However, this point is controversial (Desh pande et ai., 1992) . Loss of electrical activity for> 5 h strongly predicts the development of severe neu ronal loss in the underlying cortex following single or repeated ischemic episodes in fetal sheep (Mal lard et ai., 1992; Williams et ai., 1992) . The produc tion of nerve growth factor, a trophic factor that supports cholingeric neurons, is reduced following hypoxic-ischemic injury (Shigeno et ai., 1991) .
Exogenous nerve growth factor can reduce neu ronal loss in the CAl region of the hippocampus when given 15 min postischemia to gerbils (Shigeno et ai., 1991) . Similarly, exogenous fibroblast growth factor can prevent loss of neurons when given after CNS injury (Anderson et ai., 1988; Yamada et ai., 1991) . The neurotrophic effects of fibroblast growth factor may be mediated by IGF-l (Drago et ai., 1991) . IGF-l can promote the survival of a wide range of types of neurons and cells in vitro (Knusel et ai., 1990; Svrzic and Schubert, 1990; Barres et aI., 1992) , protect neurons against calcium mediated hypoglycemic injury (Cheng and Mattson, 1992) , and facilitate peripheral nerve regeneration (Kanje et ai., 1989) . Thus, exogenous IGF-l may provide trophic support during the critical period after injury and thus prevent the induction of mech anisms of cell death.
The dose-response curve suggests that further studies at higher doses are needed to determine the maximum effective dose. Investigations will be nec essary to determine whether IGF-l treatment can improve long-term functional outcome. The capac ity for exogenous IGF-l to reduce loss of both neu rons and glia in the hippocampus, striatum, and cor tex suggests that this peptide may provide worth while trophic support to injured cells in most cerebral structures after transient hypoxic-ischemic injuries.
